Dolutegravir
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) [1][2].
Product Specifications
CAS Number
[1051375-16-6]
Product Name Alternative
S/GSK1349572
UNSPSC
12352005
Hazard Statement
H400, H410
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Dolutegravir.html
Purity
99.85
Solubility
DMSO : 35 mg/mL (ultrasonic)
Smiles
FC1=CC(F)=C(C=C1)CNC(C2=CN(C3=C(C2=O)O)C[C@@]([H])(N4C3=O)OCC[C@H]4C)=O
Molecular Formula
C20H19F2N3O5
Molecular Weight
419.38
Precautions
H400, H410
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1
Citation 01
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Bacillus licheniformis UPF0398 protein BLi02355/BL05236 (BLi02355, BL05236)
Recombinant Bacillus licheniformis UPF0398 protein BLi02355/BL05236 (BLi02355, BL05236)
